Large Randomized Trial Finds Oxytocin Does Not Substantially Affect Empathy
A randomized clinical trial found no substantial modulation of empathy-related brain or behavioral responses by intranasal oxytocin, challenging the popular narrative of oxytocin as the "empathy hormone."
Quick Facts
What This Study Found
Randomized clinical trial showed no substantial modulation of empathy-related behavioral or neural responses by intranasal oxytocin administration compared to placebo.
Key Numbers
N=25 males; double-blind crossover; 3 empathy tasks; bilateral amygdala increase for physical pain only; OXTR rs53576 no interaction
How They Did This
Randomized controlled clinical trial. Intranasal oxytocin vs placebo. Empathy-related behavioral and brain response measures.
Why This Research Matters
The "oxytocin = empathy" narrative has influenced research funding, therapeutic trials, and public understanding. This negative result recalibrates expectations and directs research toward oxytocin's actual effects rather than assumed ones.
The Bigger Picture
Oxytocin's effects are more nuanced than the popular narrative suggests. Rather than a simple "empathy booster," oxytocin may modulate social attention, salience, or context-dependent social processing in ways too complex for simple empathy tests to capture.
What This Study Doesn't Tell Us
Single-dose acute study. Empathy measurement tools may not capture all aspects of social cognition. Oxytocin effects may be context-dependent or appear only in specific populations.
Questions This Raises
- ?Does oxytocin affect social cognition through mechanisms other than empathy?
- ?Were previous positive empathy results driven by small sample sizes and publication bias?
- ?Would chronic oxytocin produce different empathy effects than a single dose?
Trust & Context
- Key Stat:
- Not the empathy hormone A well-designed randomized trial found no substantial empathy enhancement from intranasal oxytocin — previous positive results may have been overblown by small studies
- Evidence Grade:
- High evidence: randomized, controlled clinical trial with behavioral and neural measures. Important negative result.
- Study Age:
- Published 2021. Oxytocin research continues to be refined with larger, more rigorous trials.
- Original Title:
- Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism.
- Published In:
- Scientific reports, 11(1), 15056 (2021)
- Authors:
- Mayer, Annalina V(2), Wermter, Anne-Kathrin, Stroth, Sanna(2), Alter, Peter, Haberhausen, Michael, Stehr, Thomas, Paulus, Frieder M, Krach, Sören, Kamp-Becker, Inge
- Database ID:
- RPEP-05591
Evidence Hierarchy
Frequently Asked Questions
Does oxytocin really boost empathy?
Despite the popular "empathy hormone" label, this rigorous clinical trial found no substantial empathy enhancement from intranasal oxytocin. Previous positive results from smaller studies may have been inflated by publication bias and small sample sizes.
If not empathy, what does oxytocin actually do?
Oxytocin likely affects social processing in more subtle ways — modulating attention to social cues, stress responses, and context-dependent social behavior rather than simply boosting empathy. Its effects may be more apparent in specific populations (like ASD) than in healthy individuals.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05591APA
Mayer, Annalina V; Wermter, Anne-Kathrin; Stroth, Sanna; Alter, Peter; Haberhausen, Michael; Stehr, Thomas; Paulus, Frieder M; Krach, Sören; Kamp-Becker, Inge. (2021). Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism.. Scientific reports, 11(1), 15056. https://doi.org/10.1038/s41598-021-94407-x
MLA
Mayer, Annalina V, et al. "Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism.." Scientific reports, 2021. https://doi.org/10.1038/s41598-021-94407-x
RethinkPeptides
RethinkPeptides Research Database. "Randomized clinical trial shows no substantial modulation of..." RPEP-05591. Retrieved from https://rethinkpeptides.com/research/mayer-2021-randomized-clinical-trial-shows
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.